HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $32 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Revolution Medicines (NASDAQ:RVMD) and maintained a price target of $32.
August 04, 2023 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revolution Medicines has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $32.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Revolution Medicines. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100